A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment with Standard of Care Therapy with an Immune Checkpoint Inhibitor

This trial is being run to find out how well the trial drug GEN1046 acts against NSCLC and if it is safe both as single treatment and in combination with Pembrolizumab to treat your NSCLC. Genmab also wants to learn more about the potential side effects subjects may get when they are treated with GEN1046 as single treatment or in combination with Pembrolizumab to treat NSCLC.